Two treatments per year as opposed to 12, what’s not to like? In two words—surgical implants. That’s the stigma Genentech will potentially face as it …

Even as Biogen dominates biopharma headlines with its high-profile Aduhelm launch, the company’s budding biosimilar business has been quietly building up—and now, it has another …